若您需要咨询产品或有任何技术问题,请通过官方电话 400 885 9050 或邮箱 info.cn@stemcell.com 与我们联系

EasySep™ HLA嵌合体全血CD33正选试剂盒

免疫磁珠正选人CD33+髓系细胞

产品号 #(选择产品)

产品号 #17885_C

免疫磁珠正选人CD33+髓系细胞

产品优势

  • 操作简单、快速
  • 纯度高达99%
  • 无需分离柱

产品组分包括

  • EasySep™ HLA嵌合全血CD3正选试剂盒(产品号#17885)
    • EasySep™ HLA嵌合全血CD3正选抗体混合物,3 x 1 mL
    • EasySep™ Dextran RapidSpheres™ 50101 磁珠,3 x 1 mL
    • EasySep™ 10X浓缩红细胞裂解试剂,10 mL(产品号#20110)    
  • RoboSep™ HLA嵌合全血CD33阳性分选试剂盒(含过滤枪头)(产品号#17885RF)
    • EasySep™ HLA嵌合全血CD3正选抗体混合物,3 x 1 mL
    • EasySep™ Dextran RapidSpheres™ 50101 磁珠,3 x 1 mL
    • EasySep™ 10X浓缩红细胞裂解试剂,10 mL(产品号#20110)    
    • RoboSep™ 缓冲液(产品号 #20104)
    • RoboSep™过滤枪头(产品号 #20125)
专为您的实验方案打造的产品
要查看实验方案所需的所有配套产品,请参阅《实验方案与技术文档》

总览

使用EasySep™ HLA嵌合全血CD33正选试剂盒,通过免疫磁珠正选技术,从新鲜人全血或白膜层样本中分离高纯度人CD33+髓系细胞。EasySep™技术结合单克隆抗体的特异性和无柱磁珠系统的简便性,已在发表的研究中广泛应用超过20年。

在此EasySep™正选流程中,目的细胞通过被CD33的抗体复合物及磁珠结合标记,并通过 EasySep™ 磁极进行无柱分选,只需倾倒非目标细胞即可,目标细胞则保留在管中。分选后的细胞可立即用于下游应用,例如流式 、细胞培养、或DNA/RNA提取以用于谱系特异性嵌合分析。CD33抗原在髓系祖细胞、粒细胞和单核细胞表面表达。

本产品取代EasySep™人全血CD33阳性分选试剂盒(产品号#18287)和EasySep™ HLA全血CD33阳性分选试剂盒(产品号#18287HLA),可实现更快速的细胞分离。

深入了解免疫磁珠EasySep™技术的工作原理,或如何通过RoboSep™实现全自动化的免疫磁珠细胞分选,以节省时间并提升实验室通量。探索更多为您的实验流程优化的产品,包括细胞表征、冷存等相关产品。

磁极兼容性
• “The Big Easy” EasySep™磁极(产品号 #18001) • EasyEights™ EasySep™磁极(产品号 #18103) • RoboSep™-S(产品号 #21000)
 
分类
细胞分选试剂盒
 
细胞类型
粒细胞及其亚群,髓系细胞
 
种属

 
样本来源
白膜层、全血
 
分选方法
正选
 
应用
细胞分选
 
品牌
EasySep
 
研究领域
嵌合体,HLA,免疫
 

实验数据

Typical EasySep™ HLA Chimerism Whole Blood CD33 Positive Selection Profile

Figure 1. Typical EasySep™ HLA Chimerism Whole Blood CD33 Positive Selection Profile

Starting with fresh whole blood, the CD33+ cell content of the isolated fraction is typically 96 ± 2% (mean ± SD) using “The Big Easy” EasySep™ Magnet. In the above example, the purities of the start (as assessed by labeling with anti-CD33) and the final isolated fractions are 68.0% and 96.2% (as assessed by labeling with anti-CD14 and anti-CD66b), respectively.
NOTE: RBCs were removed from the start sample by lysis prior to flow cytometry.

产品说明书及文档

请在《产品说明书》中查找相关支持信息和使用说明,或浏览下方更多实验方案。

Document Type
Product Name
Catalog #
Lot #
Language
Catalog #
17885RF
Lot #
All
Language
English
Catalog #
17885
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Catalog #
17885RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Catalog #
17885RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 3
Catalog #
17885RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 4
Catalog #
17885RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Catalog #
17885
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Catalog #
17885
Lot #
All
Language
English
Document Type
Safety Data Sheet 3
Catalog #
17885
Lot #
All
Language
English

应用领域

本产品专为以下研究领域设计,适用于工作流程中的高亮阶段。探索这些工作流程,了解更多我们为各研究领域提供的其他配套产品。

相关材料与文献

技术资料 (11)

文献 (1)

Antibody-Mediated LILRB2-Receptor Antagonism Induces Human Myeloid-Derived Suppressor Cells to Kill Mycobacterium tuberculosis. V. K. Singh et al. Frontiers in immunology 2022

Abstract

Tuberculosis is a leading cause of death in mankind due to infectious agents, and Mycobacterium tuberculosis (Mtb) infects and survives in macrophages (MФs). Although MФs are a major niche, myeloid-derived suppressor cells (MDSCs) are an alternative site for pathogen persistence. Both MФs and MDSCs express varying levels of leukocyte immunoglobulin-like receptor B (LILRB), which regulate the myeloid cell suppressive function. Herein, we demonstrate that antagonism of LILRB2 by a monoclonal antibody (mab) induced a switch of human MDSCs towards an M1-macrophage phenotype, increasing the killing of intracellular Mtb. Mab-mediated antagonism of LILRB2 alone and its combination with a pharmacological blockade of SHP1/2 phosphatase increased proinflammatory cytokine responses and phosphorylation of ERK1/2, p38 MAPK, and NF-kB in Mtb-infected MDSCs. LILRB2 antagonism also upregulated anti-mycobacterial iNOS gene expression and an increase in both nitric oxide and reactive oxygen species synthesis. Because genes associated with the anti-mycobacterial function of M1-MФs were enhanced in MDSCs following mab treatment, we propose that LILRB2 antagonism reprograms MDSCs from an immunosuppressive state towards a pro-inflammatory phenotype that kills Mtb. LILRB2 is therefore a novel therapeutic target for eradicating Mtb in MDSCs.

更多信息

更多信息
种属 Human
Magnet Compatibility • “The Big Easy” EasySep™ Magnet (Catalog #18001) • EasyEights™ EasySep™ Magnet (Catalog #18103) • RoboSep™-S (Catalog #21000)
样本来源 Buffy Coat, Whole Blood
Selection Method Positive
标记抗体
质量保证:

产品仅供研究使用,不用于针对人或动物的诊断或治疗。 欲获悉更多关于STEMCELL的质控信息,请访问 STEMCELL.CN/COMPLIANCE.
Copyright © 2025 by STEMCELL Technologies. All rights reserved.